Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
294 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape. Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 20, 26, 13, 2, 11, 8 and 1 respectively for Plaque Psoriasis (Psoriasis Vulgaris). Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) (Immunology). - The pipeline guide reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Plaque Psoriasis (Psoriasis Vulgaris) Overview 7 Therapeutics Development 8 Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 9 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 14 Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 18 Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 24 Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 79 Drug Profiles 93 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 261 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 269 Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 271 Appendix 283
List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Development by Companies, H2 2016 (Contd..3) 23 Comparative Analysis by Late Stage Development, H2 2016 24 Comparative Analysis by Clinical Stage Development, H2 2016 25 Comparative Analysis by Early Stage Development, H2 2016 26 Comparative Analysis by Unknown Stage Development, H2 2016 27 Products under Development by Companies, H2 2016 28 Products under Development by Companies, H2 2016 (Contd..1) 29 Products under Development by Companies, H2 2016 (Contd..2) 30 Products under Development by Companies, H2 2016 (Contd..3) 31 Products under Development by Companies, H2 2016 (Contd..4) 32 Products under Development by Companies, H2 2016 (Contd..5) 33 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbbVie Inc, H2 2016 34 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H2 2016 35 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2016 36 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alteogen Inc., H2 2016 37 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2016 38 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2016 39 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2016 40 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2016 41 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2016 42 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2016 43 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 44 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H2 2016 45 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2016 46 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2016 47 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cell Medica Limited, H2 2016 48 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H2 2016 49 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H2 2016 50 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H2 2016 51 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 52 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Exicure, Inc., H2 2016 53 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2016 54 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co Ltd, H2 2016 55 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2016 56 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 57 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2016 58 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2016 59 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 60 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by KPI Therapeutics, Inc., H2 2016 61 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2016 62 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2016 63 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lupin Limited, H2 2016 64 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lycera Corp., H2 2016 65 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2016 66 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by MetrioPharm AG, H2 2016 67 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 68 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 69 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2016 70 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by NeuClone Pty Ltd, H2 2016 71 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2016 72 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2016 73 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2016 74 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2016 75 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 76 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 77 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H2 2016 78 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016 79 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 80 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 81 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 82 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TheraMAB LLC, H2 2016 83 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2016 84 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2016 85 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 86 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech Inc, H2 2016 87 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H2 2016 88 Assessment by Monotherapy Products, H2 2016 89 Assessment by Combination Products, H2 2016 90 Number of Products by Stage and Target, H2 2016 92 Number of Products by Stage and Mechanism of Action, H2 2016 96 Number of Products by Stage and Route of Administration, H2 2016 100 Number of Products by Stage and Molecule Type, H2 2016 102 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2016 271 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2016 272 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2016 273 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2016 274 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2016 275 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H2 2016 276 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H2 2016 277 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..7), H2 2016 278 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2016 279 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H2 2016 280
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
